Skip to main content

Table 1 Clinical factors and systemic inflammatory status of patients receiving EGFR-TKI readministration

From: Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors

  Univariable analyses Multivariable analyses
Characteristics N (%) OS p Hazard ratio 95 % CI P value
Length of EGFR-TKI holiday    0.235    
  < 3 16 (20.0) 3.8     
 3–6 25 (31.3) 6.7     
  > 6 39 (48.8) 8.4     
PFS of first-line EGFR-TKI    0.020    <0.001
  < 6 17 (35.0) 3.5   4.970 2.170–11.382  
 6–12 35 (43.8) 7.2   1.818 0.899–3.678  
  > 12 28 (21.3) 9.9   1   
Changes in the EGFR-TKI regimen    0.474    
 Yes 75 (93.8) 7.2     
 No 5 (6.2) 8.4     
Type of EGFR-TKI readministrated    0.934    
 1st generation 71 (88.8) 7.0     
 2nd generation 9 (11.2) 7.4     
Baseline NLR    <0.001    0.037
  > 5.2 27 (34.6) 3.2   2.352 1.052–5.256  
  ≤ 5.2 51 (65.4) 8.4   1   
Trend of NLR    0.129    
  > 110 % 44 (57.1) 4.3     
  ≤ 110 % 33 (42.9) 8.4     
Baseline LMR    0.006    0.632
  > 2.5 37 (46.8) 8.3   1   
  ≤ 2.5 41 (53.2) 4.2   1.197 0.574–2.497  
Trend of LMR    0.037    0.004
  > 50 % 45 (58.4) 7.9   1   
  ≤ 50 % 32 (41.6) 4.1   2.651 1.374–5.118  
  1. Abbreviations: CI confidential interval, EGFR epidermal growth factor receptor, LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, OS overall survival, PFS progression-free survival, TKI tyrosine kinase inhibitor